Rilotumumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRilotumumab
Drug Alias Name利妥木单抗AMG-102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHepatocyte growth factor inhibitors
TargetsHepatocyte growth factor
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteAmgen Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG